AJOONI · Ajooni Biotech Ltd · Food Processing
AJOONI · Ajooni Biotech Ltd · Food Processing
As of 05 Nov close
52-week range
46.0% below 52-week high
52-week range: as of 05 Nov 2026 close.
Price chartDaily closes on the stock page.
Weighted combination of 8 measured readings. Not a probability, a rating or a forecast.
Full signal detail →Fundamentals as of 15 Sep 2026 · the company's own latest record is 52 days old
Revenue (latest Q)
₹61 Cr
Revenue YoY
PAT YoY
-38.3%
Operating margin
Revenue, last 8 quarters
P/E (TTM)
P/B
0.7
P/S (TTM)
0.3
Sector P/E
21.7
Dividend yield
0.0%
| Company | P/E | P/B | Net margin | ROE | D/E | Div. yield |
|---|---|---|---|---|---|---|
| AJOONI (this stock) | 13.9 | 0.7 | +2.4% | +4.7% | 0.19 | 0.0% |
| Nestle India | 71 | 50.7 | +15.6% | +73.9% | 0.09 | +0.9% |
| Britannia Industries | 47.6 | 24.1 | +13.3% | +51.0% | 0.27 | +1.8% |
| Tata Consumer Products | 67.4 | 4.9 | +8.1% | +7.4% | 4.18 | +0.9% |
Promoter
stable
FII
falling 1q
MF
Not available from data source
Insider trades
| Date | Insider | Type | Qty | Value |
|---|---|---|---|---|
| 26 Oct 2026 | HEALTHY BIOSCIENCES LIMITED | BUY | 90,00,000 | ₹4 |
Bulk/block deals
| date | canonicalSymbol | buy quantity | buyer count | deal strength | deal types present |
|---|---|---|---|---|---|
| 2026-09-07 | AJOONI | 0 | 0 | STRONG | BULK |
News timeline
No related news.
Concalls & investor presentations
AI-generatedNo concall transcripts or investor presentations recorded yet.
AI Summary of Annual Report
AI-generatedAjooni Biotech Limited (AJOONI) reported significant financial growth in FY2025-26, with turnover rising to ₹18,237.81 lakhs, a 59% increase from ₹11,469.18 lakhs in FY2024-25. Profit Before Tax (PBT) increased to ₹573.83 lakhs, and Profit After Tax (PAT) reached ₹432.20 lakhs. The company emphasized its strategic focus on operational efficiency, market expansion, and innovation in animal nutrition. No regulatory penalties, defaults, or legal actions were noted, and the company maintains strong compliance with corporate governance and statutory requirements. The Moringa cultivation project was discontinued due to lack of commercial viability.
- Turnover increased by 59% to ₹18,237.81 lakhs in FY2025-26.
- Profit Before Tax (PBT) rose to ₹573.83 lakhs and Profit After Tax (PAT) reached ₹432.20 lakhs.
- No regulatory actions, defaults, or legal disputes were reported during the year.
- Moringa cultivation project discontinued due to lack of commercial viability.
- Strong compliance with corporate governance and statutory requirements.
Key takeaway: Ajooni Biotech Limited delivered robust financial growth in FY2025-26 with a significant increase in turnover and profits, supported by strong operational performance and strategic initiatives, while maintaining compliance and addressing project discontinuation due to commercial viability concerns.
The following annual report excerpts provide qualitative strategic context. Do not treat any specific financial figures in these excerpts as authoritative — they may be incorrectly labeled due to PDF table extraction limitations. For precise financial data, refer to the structured fundamentals data above.
Governance disclosures
AI-generatedNeeds attention
Auditor Qualification (1 item); Regulatory Action (4 items); Default / Covenant Breach (2 items)
Items of these kinds are disclosed in the filings. This is a count of disclosed items. It is not a finding about the company and its cause has not been independently established.
Auditor Qualification
1 occurrenceEarlier (1-3 years ago)
The company did not submit the statement of cash flows along with unaudited financial results for the quarter and half year ended 30th September, 2022, leading to a fine of Rs. 1,71,10.
Regulatory Action
4 occurrencesRecent (last 12 months)
The company has been fined by the National Stock Exchange under SEBI ICDR/LODR Regulations.
Earlier (1-3 years ago)
The company did not submit the disclosure of closure of trading window for the quarter ended 30th September before the end of the quarter, and filed it on 03rd October, 2024. No penalty or fine was imposed.
Older (3+ years ago)
The company did not file the continual disclosure as required under Regulation 7(2) of SEBI (Prohibition of Insider Trading) Regulations, 2015 within two trading days of receipt of disclosure from acquirers or becoming aware of such information.
The company was fined Rs. 17,700/- by the stock exchange for a 3-day delay in disclosing related party transactions for the half year ended 31st March 2022, as required by SEBI regulations.
Default / Covenant Breach
2 occurrencesEarlier (1-3 years ago)
The excerpt mentions reviewing the reasons for substantial defaults in the payment to the debtors.
AJOONI BIOTECH LIMITED has willful defaulters and discrepancies in utilization of borrowings as per the MCA disclosures.
Routine disclosures
Contingent Liability
1 occurrenceEarlier (1-3 years ago)
Contingent liabilities not provided for include unascertained and unassessed cases of Income Tax and Sales Tax for the years 2023-24 and 2022-23.
Related-Party Transaction
5 occurrencesRecent (last 12 months)
The company discloses related-party relationships including common directors and shareholders in entities such as Punjab Biotechnology Park Limited, M/s. Khanna Solvex, Healthy Biosciences Limited, and Gilbert Kasauli Private Limited involving key management personnel and their relatives.
Earlier (1-3 years ago)
The company seeks shareholder approval for related party transactions with Healthy Biosciences Limited, a related party, involving cumulative value up to Rs. 6 Crores per financial year over three years (FY 2025-26 to FY 2027-28).
The company proposes to enter into related party transactions with Healthy Biosciences Limited, a promoter of Ajooni Biotech Limited, involving sale, purchase, or supply of goods, with an aggregate value potentially reaching Rs. 35 crores in FY2024-25.
Older (3+ years ago)
The company plans to engage in related-party transactions with an aggregate value of up to Rs. 25 crores during the financial year 2023-24, which requires shareholder approval as per Section 188 of the Companies Act, 2013.
Ajooni Biotech Limited is seeking approval for related party transactions, as mentioned in the resolution under consideration.
Management & Board Governance
2 occurrencesRecent (last 12 months)
The Managing Director cum CFO, Jasjot Singh, has resigned or been removed from their position with a governance-relevant context, as indicated by the certificate from the Company Secretary in Practice.
Earlier (1-3 years ago)
The Managing Director cum CFO of Ajooni Biotech Limited, Jasjot Singh, has signed an excerpt indicating awareness of significant fraud and potential involvement of management or employees in the company's internal control system over financial reporting.